Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Published:2009-09 Issue:Suppl 2 Volume:13 Page:
ISSN:1366-5278
Container-title:Health Technology Assessment
language:en
Short-container-title:Health Technol Assess

Author:

Boland A¹,Bagust A,Hockenhull J,Davis H,Chu P,Dickson R

Affiliation:

1. Liverpool Reviews and Implementation Group, Sherrington Buildings, University of Liverpool, Liverpool, UK

Funder

Health Technology Assessment programme

Publisher

National Institute for Health Research

Subject

Health Policy

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis;Cancers;2023-09-02

2. Treatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma;Journal of Health Economics and Outcomes Research;2020-09-04

3. A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data;Value in Health;2018-10

4. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US;Journal of Medical Economics;2018-07-06

5. Economic Evaluation of Sequential Treatments for Follicular Non-Hodgkin Lymphoma;Clinical Therapeutics;2012-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP